Rekah Pharmaceutical (Israel) Buy Hold or Sell Recommendation
| REKA Stock | ILA 1,422 16.00 1.11% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Rekah Pharmaceutical Industry is 'Strong Sell'. Macroaxis provides Rekah Pharmaceutical buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding REKA positions.
Check out Rekah Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Rekah and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Rekah Pharmaceutical Industry. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Rekah |
Execute Rekah Pharmaceutical Buy or Sell Advice
The Rekah recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Rekah Pharmaceutical Industry. Macroaxis does not own or have any residual interests in Rekah Pharmaceutical Industry or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Rekah Pharmaceutical's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Rekah Pharmaceutical Trading Alerts and Improvement Suggestions
| Rekah Pharmaceutical had very high historical volatility over the last 90 days | |
| About 37.0% of the company outstanding shares are owned by corporate insiders |
Rekah Pharmaceutical Returns Distribution Density
The distribution of Rekah Pharmaceutical's historical returns is an attempt to chart the uncertainty of Rekah Pharmaceutical's future price movements. The chart of the probability distribution of Rekah Pharmaceutical daily returns describes the distribution of returns around its average expected value. We use Rekah Pharmaceutical Industry price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Rekah Pharmaceutical returns is essential to provide solid investment advice for Rekah Pharmaceutical.
| Mean Return | -0.1 | Value At Risk | -5.51 | Potential Upside | 5.91 | Standard Deviation | 3.46 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Rekah Pharmaceutical historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Rekah Pharmaceutical Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Rekah Pharmaceutical or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Rekah Pharmaceutical's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Rekah stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.07 | |
β | Beta against Dow Jones | -0.33 | |
σ | Overall volatility | 3.37 | |
Ir | Information ratio | -0.07 |
Rekah Pharmaceutical Volatility Alert
Rekah Pharmaceutical Industry exhibits very low volatility with skewness of -0.13 and kurtosis of 0.35. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Rekah Pharmaceutical's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Rekah Pharmaceutical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Rekah Pharmaceutical Fundamentals Vs Peers
Comparing Rekah Pharmaceutical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Rekah Pharmaceutical's direct or indirect competition across all of the common fundamentals between Rekah Pharmaceutical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Rekah Pharmaceutical or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Rekah Pharmaceutical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Rekah Pharmaceutical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Rekah Pharmaceutical to competition |
| Fundamentals | Rekah Pharmaceutical | Peer Average |
| Return On Equity | 0.0222 | -0.31 |
| Return On Asset | 0.0208 | -0.14 |
| Profit Margin | 0.01 % | (1.27) % |
| Operating Margin | 0.05 % | (5.51) % |
| Current Valuation | 316.92 M | 16.62 B |
| Shares Outstanding | 11.41 M | 571.82 M |
| Shares Owned By Insiders | 37.27 % | 10.09 % |
| Shares Owned By Institutions | 42.66 % | 39.21 % |
| Price To Book | 1.11 X | 9.51 X |
| Price To Sales | 0.63 X | 11.42 X |
| Revenue | 263.95 M | 9.43 B |
| Gross Profit | 65.16 M | 27.38 B |
| EBITDA | 36.2 M | 3.9 B |
| Net Income | 6.62 M | 570.98 M |
| Cash And Equivalents | 31.61 M | 2.7 B |
| Cash Per Share | 2.77 X | 5.01 X |
| Total Debt | 101.23 M | 5.32 B |
| Debt To Equity | 1.01 % | 48.70 % |
| Current Ratio | 1.99 X | 2.16 X |
| Book Value Per Share | 14.39 X | 1.93 K |
| Cash Flow From Operations | 21.17 M | 971.22 M |
| Earnings Per Share | 0.32 X | 3.12 X |
| Number Of Employees | 399 | 18.84 K |
| Beta | 0.0605 | -0.15 |
| Market Capitalization | 193.93 M | 19.03 B |
| Total Asset | 437.09 M | 29.47 B |
| Retained Earnings | 49 M | 9.33 B |
| Working Capital | 156 M | 1.48 B |
| Current Asset | 246 M | 9.34 B |
| Current Liabilities | 90 M | 7.9 B |
| Z Score | 0.6 | 8.72 |
| Annual Yield | 0.05 % | |
| Net Asset | 437.09 M |
Rekah Pharmaceutical Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Rekah . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.045 | |||
| Daily Balance Of Power | (0.24) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 1455.5 | |||
| Day Typical Price | 1444.33 | |||
| Market Facilitation Index | 67.0 | |||
| Price Action Indicator | (41.50) | |||
| Period Momentum Indicator | (16.00) | |||
| Relative Strength Index | 51.17 |
About Rekah Pharmaceutical Buy or Sell Advice
When is the right time to buy or sell Rekah Pharmaceutical Industry? Buying financial instruments such as Rekah Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Rekah Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Technology Thematic Idea Now
Technology
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Rekah Stock
Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.